Think of it like a garbage strike.
This is how Nicholas Leeper, MD, assistant professor of vascular surgery and of cardiovascular medicine, describes the findings of a recent study of which he was senior author.
The study was published Feb. 17 in the Journal of Clinical Investigation. Yoko Kojima, MD, PhD, senior research associate, was the lead author.
Normally, the body is extremely efficient at taking out the garbage. Two hundred billion cells die every day in our bodies, and most get cleared out within a matter of seconds. But when this process breaks down and garbage, in the form of necrotic cells, starts building up in the walls of blood vessels, it’s not a good thing.
Leeper and his colleagues set out to discover why genetic variation at the chromosome 9p21 location has been repeatedly identified as the most important commonly inherited DNA sequence for a wide range of cardiovascular diseases, including stroke, heart attacks and aneurysms.
Conducting studies in mice with atherosclerosis, the researchers showed that loss of a candidate gene at this locus leads to impaired “efferocytosis” — from the Latin for “take to the grave” — the process by which dead or necrotic cells are removed. Mice with this genetic variation showed an increase in buildup of these dead cells, further advancing their atherosclerosis, as opposed to those that did not have the genetic variation.
In other words, a commonly inherited genetic variant, which is found in 20 percent of the population, contributes to the development of coronary artery disease (also known as coronary atherosclerosis) by stimulating the accumulation of necrotic debris within the evolving plaque.
“If you were born with genetic variation at the 9p21 locus, your risk of heart disease is elevated, though we haven’t understood why,” Leeper said. “This research gets at that hidden risk. You can be a nonsmoker, be thin, have low blood pressure, and still be at risk for a heart attack if you were born with this variant. This work may help explain that inherited risk factor, and more importantly help develop a new therapy to prevent the heritable component of cardiovascular disease.”
Other Stanford co-authors of the study were Ramen Kundu, PhD, senior research associate; postdoctoral scholars Clint Miller, PhD, Uwe Raaz, MD, and Frederick Dewey, MD; and Tom Quertermous, MD, professor of cardiovascular medicine.
The study was funded by the National Institutes of Health, the American Heart Association and Gilead Pharmaceuticals.
Stanford Medicine integrates research, medical education and patient care at its three institutions – Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children’s Hospital Stanford. For more information, please visit the Office of Communication & Public Affairs site at http://mednews.stanford.edu/.